Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: AIDS Care. 2019 Dec 19;33(3):290–298. doi: 10.1080/09540121.2019.1703892

Sociodemographic factors affecting viral load suppression among people living with HIV in South Carolina

Mohammad Rifat Haider a, Monique J Brown b,c, Sayward Harrison b,d, Xueying Yang b,d, LaDrea Ingram e, Amir Bhochhibhoya f, Akeen Hamilton b,d, Bankole Olatosi g, Xiaoming Li b,d
PMCID: PMC7302958  NIHMSID: NIHMS1594242  PMID: 31856584

Abstract

Adherence to antiretroviral therapy (ART) enables people living with HIV (PLWH) to reach and maintain viral suppression. As viral suppression significantly reduces risk for secondary transmission, this study aimed to examine sociodemographic factors associated with viral suppression among PLWH in South Carolina (SC). We analyzed cross-sectional data collected from 342 PLWH receiving HIV care from a large clinic in SC and provided complete information on most recent viral load, ART adherence, and sociodemographic factors. Bivariate analysis examined associations between key variables, and logistic regression was used to calculate the odds of viral suppression among select sociodemographic groups and adherence levels. Results indicated that approximately 82% of participants reported achieving viral suppression. PLWH who were older, male, and employed full-time had higher odds of being virally suppressed compared to those who were younger, female, and unemployed. PLWH with medium (adjusted Odds Ratio [aOR]: 3.79; 95% CI: 1.15–12.48) and high (aOR: 3.51; 95% CI: 1.21–10.24) levels of adherence were more likely to report viral suppression than those with low adherence. Targeted interventions are warranted for groups at-risk of low ART adherence, and healthcare providers should also be aware of contextual factors that serve as barriers to adherence for PLWH.

Keywords: HIV, viral suppression, adherence, sociodemographic

Introduction

With the advent of highly active antiretroviral therapy (ART), human immunodeficiency virus (HIV) has been largely transformed from an acute to a chronic health condition. Successful management of HIV can be achieved through an effective HIV care continuum – including initial testing, rapid linkage-to-care, engagement in-care, and ART adherence (Deeks, Lewin, & Havlir, 2013). ART adherence helps in achieving viral suppression, which, in turn, improves quality of life and reduces opportunistic infections, comorbidities, and HIV-related mortality (Cohen et al., 2011; Gill et al., 2002). The HIV care continuum is critical in reducing HIV incidence, as evidence suggests that people living with HIV (PLWH) with an undetectable viral load (VL) have effectively no risk of transmitting HIV to uninfected persons (Gardner, McLees, Steiner, Del Rio, & Burman, 2011). As a result, “Treatment as Prevention” (TasP) has become the dominant HIV prevention strategy in the United States (US) and across the globe (Dieffenbach, 2012), and has been found to be effective in preventing HIV transmission (Bavinton et al., 2018; Cohen, McCauley, & Gamble, 2012). This evidence spurred the new movement titled “Undetectable = Untransmittable (U = U)” by Prevention Access Campaign in 2016 (PAC, 2016) and endorsed by UNAIDS in 2018 (UNAIDS, 2018).

In 2016, the Centers for Disease Control and Prevention (CDC) estimated that 86% of all PLWH in the US were diagnosed, and of these, 64% were linked to HIV care, 49% were retained in-care, and 53% achieved viral suppression (CDC, 2019c). This low level of viral suppression is highly concerning as individuals with a detectable VL may transmit the virus to others (CDC, 2019d). A recent study showed that 91.5% of new HIV infections were transmitted by PLWH who were either undiagnosed or not engaged in medical care; while, less than 6% of new cases were transmitted from those receiving care and prescribed with ART (Skarbinski et al., 2015).

Compared to other US regions, in 2014, nearly half (44%) of all new HIV diagnoses were in the South, which contains only around one-third (37%) of the total population (CDC, 2016). The South also accounts for 52% of new AIDS cases in the US (CDC, 2018b). Furthermore, half (51%) of the PLWH who are unaware of their serostatus reside in the South (Reif, Safley, McAllaster, Wilson, & Whetten, 2017).

South Carolina (SC), a predominantly rural southern state, has a relatively high incidence of HIV and AIDS cases. African Americans constitute 70% (47% men, 23% women) of the total PLWH in SC (SCDHEC, 2017). In a study conducted in SC, almost a quarter of newly-diagnosed PLWH were delayed in being linked to care (i.e., 30–365 days to first CD4 or VL test after diagnosis) or were not in care at all (Gill, Babatunde, & Weissman, 2017). Cumulatively only 68% of PLWH in SC received any care during 2016, while only 53% were consistently engaged in care, and 57% were virally suppressed at their most recent test (SCDHEC, 2017). These numbers highlight the importance of tracking the progress of Southern states like SC in improving the HIV care continuum, including increasing viral suppression rates. The current study examines associations between key sociodemographic factors and adherence to ART and viral suppression among a diverse sample of PLWH in SC.

Methods

Data source and study design

In 2018, we partnered with a large immunology center (IC) in Columbia, SC to complete a cross-sectional survey with a subset of their current PLWH. The University of South Carolina Institutional Review Board approved the study. Data were collected between May and September of 2018, with all surveys completed on site at the Ryan White Program (RWP)-funded clinic. All PLWH attending the IC for follow-up HIV care visits were informed about the study. Those interested in participating were directed to a research team member, who then further explained the study and obtained informed consent from participants. Study inclusion criteria included: (1) resident of SC, (2) ≥18 years of age, (3) PLWH, and (4) willing to participate in a 35–40 min survey. Each participant received a $20 gift card in appreciation of their time and effort. The anonymous survey was administered in designated clinic areas and, when requested, in a private room. More than 80% of invited individuals agreed to participate in the survey. A total of 402 PLWH initiated the survey. A small number of individuals (n = 5) did not complete the survey due to time constraints (e.g., had to get labs, had another appointment), resulting in a total of 397 completing the survey. Due to missing data on key study variables, the final analysis for the current study included 342 PLWH.

Measures

Viral suppression

Viral suppression was measured through participant self-report. Specifically, participants were asked to report the results of their most recent VL test result. Although different organizations set undetectable VL at different levels (e.g., CDC set it at <200 copies/ml (CDC, 2019b), while San Francisco AIDS Foundation sets it at <50 copies/ml (Land, 2018), it really depends on the available test’s lower limit of detecting HIV RNA copies/ml of blood. Therefore, we used 100 copies/ml as the undetectable VL cut-off level in this study. Possible responses included undetectable, detectable but less than 100 viral copies/ml, detectable but 100 to 500 viral copies/ml, 500 to 5000 viral copies/ml, greater than 5000 viral copies/ml, and “I don’t know”. For the current study, a VL was considered undetectable if <100 copies/ml – a stricter threshold than the current threshold that is used by the CDC (i.e., (i.e., <200 copies/ml) (CDC, 2019b). Thus, if the participant reported an undetectable VL or a VL of<100 viral copies/ml, we defined the participant as virally suppressed.

ART adherence

Self-reported ART adherence was measured by four items adopted from the Adult AIDS Clinical Trials Group adherence instrument (Chesney et al., 2000). The items were modified to consider ART adherence over last month. Three items asked PLWH to report whether they had missed their medication “yesterday”, the “day before yesterday”, and “over the past weekend (Saturday/Sunday)”. Another item asked PLWH to estimate how frequently they missed a dose of ART over a typical month, with options including never miss, miss less than one day, miss one to three days, miss three to five days, and miss at least six days. Cronbach’s alpha of the ART adherence scale was 0.63, indicating acceptable internal reliability. A single indicator of ART adherence was generated by a principal component analysis which assessed the factor structure of the four adherence items. The eigenvalue was 2.46 for the first component and 0.62 for the second component, which strongly suggested a single factor structure. Accordingly, based on the ART adherence factor score, we categorized patients into three tertiles containing a third of the population in each. The “low adherence” tertile had a cutoff value of 0.07, the “medium adherence” tertile had a cutoff value of 0.51, and the “high adherence” tertile had a cutoff value of 0.95.

Sociodemographic variables

Participants reported on a number of sociodemographic variables that have been previously associated with viral suppression (Mugavero, Amico, Horn, & Thompson, 2013). Participants were asked to report their age (18–29, 30–49, ≥50 years), gender (male, female), sexual orientation (“lesbian, gay or bisexual”, and heterosexual), race (African American, White, other), marital status (married/living together, never married, other), educational attainment (grades 1–11, grade 12 or GED, some college, Bachelor’s degree or higher), employment status (unable to work/unemployed, employed part-time, employed full-time, other), annual household income (<$10,000, $10,000–$24,999, $25,000–$49,999, ≥$50,000), and whether they had been previously incarcerated (no, yes).

Statistical analysis

First, we generated descriptive statistics for sociodemographic variables (Table 1). Next, we used bivariate analysis (chi-square test for categorical variables) to examine associations between our key variables of interest (Table 2). Finally, to examine the association between sociodemographic factors, ART adherence, and viral suppression, logistic regression was used to calculate the adjusted odds ratios (aOR) and 95% confidence intervals (95%CI) of reporting viral suppression (Table 3). In the adjusted model we included all sociodemographic variables and ART adherence because these variables were found to be significantly correlated with viral suppression in prior research (Blank et al., 2015; Chakraborty et al., 2015; Mugavero et al., 2013). We chose not to exclude any variables found to be nonsignificant in bivariate analysis because this type of variable selection often rejects potentially important variables (Sun, Shook, & Kay, 1996). Due to casewise deletion (deleting observations with covariates with missing values) the resultant sample size was 193 for the multivariable analysis. All analyses were performed with Stata 14.2 (StataCorp, 2015).

Table 1.

Social demographic and HIV-related characteristics of the PLWH, N = 342.

Characteristics n (%)
Viral suppression
 No 63 (18.4)
 Yes 279 (81.6)
Age
 18–29 Years 71 (18.4)
 30–49 Years 163 (42.1)
 ≥50 Years 153 (39.5)
Sex
 Female 135 (34.3)
 Male 258 (65.7)
Sexual orientation
 Lesbian, gay or bisexual 203 (53.3)
 Heterosexual 178 (46.7)
Race
 Other 21 (5.2)
 White 67 (16.8)
 Black 312 (78.0)
Marital status
 Married/Living together 69 (21.0)
 Never married 193 (58.6)
 Other 67 (20.4)
Education
 Grades 1–11 51 (15.4)
 Grade 12 or GED 104 (31.3)
 Some college 114 (34.3)
 Bachelor or higher 63 (19.0)
Employment
 Full-time 133 (40.2)
 Part-time/Other 81 (24.5)
 Unable to work/unemployed 117 (35.3)
Annual household income
 <$10,000 135 (36.0)
 $10,000-$24,999 106 (28.3)
 $25,000-$49,999 90 (24.0)
 ≥$50,000 44 (11.7)
Incarceration history
 No 235 (68.7)
 Yes 107 (31.3)
Adherence to ART
 Low 105 (30.8)
 Medium 77 (22.6)
 High 159 (46.6)
Total 342 (100.0)

Due to missing data, some variables do not have 342 observations.

Table 2.

Bivariate analysis of viral suppression by demographic and HIV-related characteristics of PLWH, n = 342.

Characteristics Viral suppression p-Value
No n (%) Yesn (%)
Age 0.001
 18–29 Years 20 (32.8) 41 (67.2)
 30–49 Years 27 (19.2) 114 (80.8)
 ≥50 Years 14 (10.7) 117 (89.3)
Sex 0.147
 Female 24 (22.6) 82 (77.4)
 Male 37 (16.1) 193 (83.9)
Sexual orientation 0.485
 Lesbian, gay and bisexual 31 (16.8) 154 (83.2)
 Heterosexual 29 (19.7) 118 (80.3)
Race 0.290
 Other 3 (15.8) 16 (84.2)
 White 7 (11.7) 53 (88.3)
 Black 53 (20.2) 209 (79.8)
Marital status 0.001
 Married/Living together 9 (15.5) 49 (84.5)
 Never married 44 (27.1) 118 (72.8)
 Other 3 (5.4) 53 (94.6)
Education 0.005
 Grades 1–11 8 (23.5) 26 (76.5)
 Grade 12 or GED 24 (30.4) 55 (69.6)
 Some college 20 (19.2) 84 (80.8)
 Bachelor’s or higher 4 (6.5) 58 (93.5)
Employment 0.070
 Full-time 17 (14.7) 85.3 (99)
 Part-time/Other 13 (18.8) 81.2 (56)
 Unable to work/unemployed 25 (27.5) 66 (72.5)
Annual household income 0.036
 <$10,000 25 (23.2) 83 (76.8)
 $10,000-$24,999 20 (21.3) 74 (78.7)
 $25,000-$49,999 12 (14.5) 71 (85.5)
 ≥$50,000 2 (4.7) 41 (93.3)
Incarceration history 0.326
 No 34 (16.4) 174 (83.6)
 Yes 18 (21.2) 67 (78.8)
Adherence to ART 0.116
 Low 22 (24.2) 69 (75.8)
 Medium 13 (18.3) 58 (81.7)
 High 20 (13.6) 127 (86.4)

Table 3.

Multivariable model for key sociodemographic factors associated with viral suppression among PLWH in South Carolina (n = 193).

Characteristics Unadjusted odds ratio 95% CI p-Value Adjusted odds ratio 95% CI p-Value
Age
 18–29 Years Ref. Ref.
 30–49 Years 2.06* 1.04–4.06 0.037 3.29* 1.01–10.34 0.048
 ≥50 Years 4.08*** 1.89–8.81 0.000 6.22* 1.29–27.39 0.022
Sex
 Female Ref. Ref.
 Male 1.53 0.86–2.71 0.149 4.35* 1.04–18.22 0.043
Sexual orientation
 Lesbian, gay, or bisexual Ref. Ref.
 Heterosexual 0.82 0.47–1.43 0.485 0.68 0.18–2.55 0.566
Race
 Other Ref. Ref.
 White 1.42 0.33–6.13 0.639 1.55 0.14–17.03 0.720
 Black 0.74 0.21–2.63 0.641 0.77 0.10–5.71 0.799
Marital status
 Other Ref. Ref.
 Married/Living together 0.31 0.79–1.20 0.091 0.11* 0.01–0.74 0.024
 Never married 0.15** 0.05–0.51 0.002 0.09* 0.02–0.56 0.010
Education
 Bachelor or higher Ref. Ref.
 Grades 1–11 0.22* 0.06–0.81 0.023 0.25 0.04–1.47 0.125
 Grade 12 or GED 0.16** 0.05–0.48 0.001 0.26 0.06–1.06 0.060
 Some college 0.29* 0.09–0.89 0.031 0.69 0.18–2.68 0.592
Employment
 Unable to work/ unemployed Ref. Ref.
 Full-time 2.21* 1.11–4.40 0.025 4.03* 1.27–12.83 0.018
 Part-time/Other 1.63 0.76–3.49 0.206 2.75 0.78–9.73 0.117
Annual household income
 <$10,000 Ref. Ref.
 $10,000-$24,999 1.11 0.57–2.17 0.750 0.21* 0.06–0.73 0.014
 $25,000-$49,999 1.78 0.84–3.80 0.135 0.11** 0.03–0.52 0.005
 ≥$50,000 6.17* 1.39–27.35 0.016 0.78 0.06–10.61 0.851
Incarceration history
 No Ref. Ref.
 Yes 0.73 0.38–1.38 0.327 0.39 0.13–1.19 0.096
Adherence to ART
 Low Ref. Ref.
 Medium 1.42 0.66–3.07 0.369 3.79* 1.15–12.48 0.028
 High 2.02* 1.03–3.97 0.040 3.51* 1.21–10.24 0.021
***

p-Value < 0.0001;

**

p-Value < 0.001;

*

p-Value < 0.01.

Results

In Table 1 we present the demographic characteristics of the study participants. Approximately four in ten participants (42.1%) were aged 30–49, and more than one-third (39.5%) of participants were over 50 years old. The majority of the sample (65.7%) was male, with 34.3% identifying as female. More than half (53.3%) reported being lesbian, gay, or bisexual, and more than three-quarters (78.0%) were African American. More than half (58.6%) of the sample were never married, one-third (34.4%) had some college education, two-fifths (40.2%) were employed full-time, and more than one-third (36.0%) reported an annual household income of less than $10,000. Almost one-third (31.3%) reported that they had previously been incarcerated. Nearly half (46.6%) of participants reported a high level of ART adherence and more than four-fifths (81.6%) reported an undetectable VL.

The results of the bivariate analyses are shown in Table 2. There were statistically significant differences in viral suppression by age, marital status, education, and annual household income.

Table 3 shows results of the multivariable analysis that was conducted to assess associations between sociodemographic factors, ART adherence, and viral suppression. In the adjusted model, PLWH aged 30–49 years (adjusted odds ratio [aOR] = 3.29, 95% CI = 1.01–10.34) and ≥50 years (aOR = 6.22, 95% CI = 1.29–27.39) had higher odds of being virally suppressed PLWH aged 18–29 years. Men (aOR = 4.35, 95% CI = 1.04–18.22) than females had higher chance of being virally suppressed. PLWH wo were employed full-time (aOR = 4.03, 95%CI = 1.27–12.83) than unemployed/unable to work had higher odds of being virally suppressed. PLWH with medium levels of adherence (aOR = 3.79, 95%CI = 1.15–12.48) and high levels of adherence (aOR = 3.55, 95%CI = 1.21–10.24) than those with low levels. PLWH who were married/living together (aOR = 0.11, 95% CI = 0.01–0.74) and never married (aOR = 0.09, 95% CI = 0.02–0.56) had lower odds of viral suppression than those with other relationship status, PLWH with a household annual income of $10,000–$24,499 (aOR = 0.21, 95%CI = 0.06–0.73) and $25,000–$49,999 (aOR = 0.11, 95%CI = 0.03–0.52) had lower odds of viral suppression than those with an annual household income of <$10,000.

Discussion

Participants in this study reported high overall rates of viral suppression, which has important implications in for reducing the HIV epidemic in the Southern US. These high rates show that PLWH who are linked-to-care can achieve viral suppression and strengthen the HIV care continuum. Participants in this study reported a rate of viral suppression of 81.6%, which is higher than the current statewide estimate (53%) (SCDHEC, 2017) and is also higher than current national estimates of viral suppression (49%) (CDC, 2018a). These differences could be explained by having recruited participants from a comprehensive HIV care center, as it is likely that these PLWH had better quality of HIV care. However, there is still a need for improvement in testing, linkage, retention in care, and viral suppression to attain the targets set by the National HIV/AIDS Strategy (The White House, 2016). Understanding differences in viral suppression rates among various sub-populations in the Southern US may help to determine potential target populations for future tailored interventions.

Our findings showed that older PLWH were more likely to achieve viral suppression compared to younger PLWH. Similar results were found in other studies (Chakraborty et al., 2015; Crepaz, Dong, Wang, Hernandez, & Hall, 2018). One study conducted in SC found that youth (aged 13–19) were slower to achieve reductions in VL (Chakraborty et al., 2015). Similarly, a nationwide study found that African American PLWH (aged 13–24 years) had the lowest prevalence of sustained viral suppression (Crepaz et al., 2018). Young people (13–24 years) constitute about a quarter of the new infections and an estimated 60% of these youth PLWH are unaware of their serostatus (CDC, 2013).

Women living with HIV in the current study had lower odds of achieving viral suppression compared to men. This is consistent with multiple studies from the US (Chakraborty et al., 2015; Nance et al., 2018; Xia, Robbins, Lazar, Torian, & Braunstein, 2017). Other studies have also documented that women living with HIV are vulnerable to experiencing delayed care, greater stigma and other barriers, and poorer health outcomes (Aziz & Smith, 2011). These barriers may reduce medication adherence leading to lower rates of viral suppression. Moreover, existing literature on adherence in other higher-income countries suggests that women are less likely to adhere to ART than men and recommends specialized care for women to increase their adherence (Puskas et al., 2011). Future research should explore the needs of women across the HIV care continuum to better understand unique barriers at each stage.

In our study, PLWH with higher educational attainment were more likely to be virally suppressed, which may be due to have higher health literacy (Kalichman, Ramachandran, & Catz, 1999), or higher levels of knowledge and understanding about HIV (Kalichman et al., 2000; Kalichman & Rompa, 2000). As a result, they may be more likely to access care, adhere to ART, and thus attain viral suppression.

PLWH who were employed full-time were more likely to be virally suppressed. Similar socioeconomic disparities in viral suppression have been reported in the United Kingdom (Burch et al., 2016) and US (Hussen et al., 2018; Xia et al., 2017). Another study noted that unemployment was associated with twice the adjusted risk of virologic failure (Saracino et al., 2016). Socioeconomic status could impact virologic outcomes by delays in receiving a timely HIV diagnosis (Girardi, Sabin, & Monforte, 2007), low CD4 count at ART initiation (Le Moing et al., 2002), differences in experiences or quality of health care, and pharmacokinetics (e.g., nutrition deficiencies) (Weiser et al., 2009). Conversely, our results show that middle-income PLWH had lower odds of achieving viral suppression than low-income PLWH. More research is warranted to understand this surprising finding, but potential hypothesis included that the lower-income PLWH may be linked to more federal and state programs or receive more services funded through the Ryan White Program. In one recent study, uninsured patients supported through the program more likely to be virally suppressed (Bradley et al., 2015) than uninsured patients without assistance. These findings highlight the need for policies that ensure that all PLWH have access to comprehensive HIV care, ART, and social services (e.g., employment and income assistance).

Finally, in our study, high levels of ART adherence were positively associated with higher odds of viral suppression. This finding is consistent with current scientific evidence and clinical guidelines supporting immediate and lifelong adherence to ART (Howard et al., 2002; Sithole et al., 2018; Ti et al., 2014).

Limitations

The study had several limitations. First, all patients were currently receiving care at comprehensive IC in SC. This sample included in the analysis (N = 342) represents ~2.6% of the total population of PLWH in SC who received HIV care in 2017 (N = 13,348) (SCDHEC, 2017). However, the sample is not representative of all PLWH in SC and may underrepresent rural patients. Moreover, rather than using electronic medical records, we relied on self-reported levels of viral suppression. Recall bias may impact results, although, previous studies have suggested that PLWH who are in care are able to provide accurate information with regard to their VL (Carter et al., 2017; Grabowski et al., 2018; Sewell et al., 2017). Future studies should seek to incorporate more objective measures (i.e., biomarkers) of viral suppression and adherence, and use other methods (e.g., adherence monitoring devices) to confirm self-reports. In addition, while self-reported ART adherence has shown a strong correlations with virologic response (DeMasi et al., 2001; Shi et al., 2010) and adherence monitoring devices (Arnsten et al., 2001), future studies may use the latter along with patient self-report. In a post-hoc analysis for missing data, we found that there were some significant differences in participants who were excluded from the analysis due to missing data, in terms of gender, sexual orientation, education, annual household income, and incarceration history. Thus, the associations between these variables and viral suppression might be biased in the current analysis. However, as discussed before, PLWH with these characteristics (i.e., females, low education, low income) had lower odds of viral suppression. Therefore, it is likely that the associations in the current study are underestimates of the “true association.”

Similarly, neither sexual orientation nor incarceration history was associated with the outcome; however, the missing data remains a limitation. In addition, the wide confidence intervals for some variables in the multivariable model may indicate sparse data bias (i.e., some combinations of variables may lack adequate case numbers resulting in a lack of power to detect statistically significant differences) (Greenland, Mansournia, & Altman, 2016).

Conclusions

Despite these limitations, this study identifies important factors associated with viral suppression of PLWH in SC and has important implications for HIV treatment and care. These findings highlight the need for the development of intervention strategies that target PLWH who are most at-risk for failing to reach and maintain viral suppression in the Southern US. Particularly, targeted approaches in SC may be needed to helpyoung and unemployed PLWH as well as women living with HIV to achieve viral suppression. As adherence is critical to viral suppression, identifying facilitators and barriers to adherence that are encountered by PLWH in the Southern US is critical to improving individual outcomes and reducing the incidence of secondary transmission across the region. Such findings can also be helpful in developing adherence interventions and advocating for policy changes that support effective patient-provider partnerships (CDC, 2019a).

Acknowledgements

This study was funded in part by the South Carolina SmartState Program®. The authors would like to acknowledge the contribution of the participants in this study. We also would like to give a special thanks to the staff at the immunology center where this study was conducted and the research team without whose dedication and expertise, this study could not have been conducted.

Funding

Data collection for this study was funded by the South Carolina SmartState Program® (https://smartstatesc.org/). MRH, BO, and XL were supported by the National Institutes of Allergey and Infectious Diseases of the National Institutes of Health under Award Number R01AI127203. MJB is supported by the National Institute of Mental Health of the National Institutes of Health under Award Number K01MH115794. SEH is supported by the National Institute of Mental Health of the National Institutes of Health under Award Number K01MH118073. The content is solely the responsibility of the authors and does not necessarily represent the offcial views of the National Institutes of Health.

Appendix

Table A1.

Table: post-hoc analysis for missing data.

Characteristics Included in analysis p-Value
N = 60 No n (%) N = 342 Yes n (%)
Age 0.974
 18–29 Years 10 (14.1) 61 (85.9)
 30–49 Years 22 (13.5) 141 (86.5)
 ≥50 Years 22 (14.4) 131 (85.6)
Sex 0.004
 Female 29 (21.5) 106 (78.5)
 Male 28 (10.9) 230 (89.1)
Sexual orientation 0.013
 Lesbian, gay and bisexual 31 (16.8) 154 (83.2)
 Heterosexual 29 (19.7) 118 (80.3)
Race 0.397
 Other 2 (9.5) 19 (90.5)
 White 7 (10.5) 60 (89.5)
 Black 50 (16.0) 262 (84.0)
Ethnicity 0.399
 Hispanic 3 (11.7) 13 (88.3)
 Non-hispanic 37 (18.7) 279 (81.3)
Marital status 0.997
 Married/Living together 11 (15.9) 58 (84.1)
 Never married 31 (16.1) 162 (83.9)
 Other 11 (16.4) 56 (83.6)
Education 0.000
 Grades 1–11 17 (33.3) 34 (66.7)
 Grade 12 or GED 25 (24.0) 79 (76.0)
 Some college 10 (8.8) 104 (91.2)
 Bachelor’s or higher 1 (1.6) 62 (98.4)
Employment 0.119
 Full-time 17 (14.7) 116 (87.2)
 Part-time/Other 12 (18.8) 69 (85.2)
 Unable to work/unemployed 26 (27.5) 91 (77.8)
Annual household income 0.004
 <$10,000 27 (20.0) 108 (80.0)
 $10,000-$24,999 12 (11.3) 94 (88.7)
 $25,000-$49,999 7 (7.8) 83 (92.2)
 ≥$50,000 1 (2.3) 43 (97.7)
Incarceration history 0.026
 No 27 (11.5) 208 (88.5)
 Yes 22 (20.6) 85 (79.4)
Adherence to ART 0.248
 Low 14 (13.3) 91 (67.2)
 Medium 6 (7.8) 71 (92.2)
 High 12 (7.6) 147 (92.4)

Footnotes

Disclosure statement

No potential conflict of interest was reported by the authors.

Data availability statement

The data that support the findings of this study can be available on request from the SC SmartState Center for Health Care Quality.

References

  1. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, … Schoenbaum EE (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33(8), 1417–1423. doi: 10.1086/323201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aziz M, & Smith KY (2011). Challenges and successes in linking HIV-infected women to care in the United States. Clinical Infectious Diseases, 52(Suppl_2), S231–S237. [DOI] [PubMed] [Google Scholar]
  3. Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, … Pinto AN (2018). Viral suppression and HIV transmission in serodiscordant male couples: An international, prospective, observational, cohort study. The Lancet HIV, 5(8), e438–e447. [DOI] [PubMed] [Google Scholar]
  4. Blank AE, Fletcher J, Verdecias N, Garcia I, Blackstock O, & Cunningham C (2015). Factors associated with retention and viral suppression among a cohort of HIV+ women of color. AIDS Patient Care and STDs, 29(S1), S27–S35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bradley H, Viall AH, Wortley PM, Dempsey A, Hauck H, & Skarbinski J (2015). Ryan White HIV/AIDS Program assistance and HIV treatment outcomes. Clinical Infectious Diseases, 62(1), 90–98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Burch LS, Smith CJ, Anderson J, Sherr L, Rodger AJ, O’Connell R, … Lampe FC (2016). Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: Cross-sectional and longitudinal analyses. The Lancet Public Health, 1(1), e26–e36. doi: 10.1016/S2468-2667(16)30002-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carter A, de Pokomandy A, Loutfy M, Ding E, Sereda P, Webster K, … Kaida A (2017). Validating a self-report measure of HIV viral suppression: An analysis of linked questionnaire and clinical data from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study. BMC Research Notes, 10(1), 138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. CDC. (2013). HIV among youth in the US.
  9. CDC. (2016, May). HIV in the Southern United States. Retrieved from https://www.cdc.gov/hiv/pdf/policies/cdchiv-in-the-south-issue-brief.pdf
  10. CDC. (2018a). HIV in the United States. Retrieved from https://www.cdc.gov/hiv/images/library/infographics/continuum-infographic.png
  11. CDC. (2018b, November 27). HIV in the United States by geography. Retrieved from https://www.cdc.gov/hiv/statistics/overview/geographicdistribution.html
  12. CDC. (2019a). Effective intervention: Partnership for health - medication adherence. Retrieved from https://effectiveinterventions.cdc.gov/en/care-medication-adherence/group2/partnership-for-health-medication-adherence
  13. CDC. (2019b, August 29). HIV treatment as prevention. Retrieved from https://www.cdc.gov/hiv/risk/art/index.html
  14. CDC. (2019c). Understanding the HIV care continuum. Retrieved from https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf [DOI] [PubMed]
  15. CDC. (2019d). Understanding the HIV care continuum. Retrieved from https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf [DOI] [PubMed]
  16. Chakraborty H, Iyer M, Duffus WA, Samantapudi AV, Albrecht H, & Weissman S (2015). Disparities in viral load and CD4 count trends among HIV-infected adults in South Carolina. AIDS Patient Care and STDs, 29(1), 26–32. doi: 10.1089/apc.2014.0158 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Chesney MA, Ickovics J, Chambers D, Gifford A, Neidig J, Zwickl B, … Patient Care Committee & Adherence Working Group Of The Outcomes Committee Of The Adult Aids Clinical Trials Group. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS Care, 12(3), 255–266. [DOI] [PubMed] [Google Scholar]
  18. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, … Fleming TR (2011). Prevention of HIV1 infection with early antiretroviral therapy. New England Journal of Medicine, 365(6), 493–505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cohen MS, McCauley M, & Gamble TR (2012). HIV treatment as prevention and HPTN 052. Current Opinion in HIV and AIDS, 7(2), 99–105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Crepaz N, Dong X, Wang X, Hernandez AL, & Hall HI (2018). Racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons receiving HIV care - United States, 2014. MMWR. Morbidity and Mortality Weekly Report, 67(4), 113–118. doi: 10.15585/mmwr.mm6704a2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Deeks SG, Lewin SR, & Havlir DV (2013). The end of AIDS: HIV infection as a chronic disease. The Lancet, 382 (9903), 1525–1533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. DeMasi RA, Graham NM, Tolson JM, Pham SV, Capuano GA, Fisher RL, … Eron JJ (2001). Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Advances in Therapy, 18(4), 163–173. [DOI] [PubMed] [Google Scholar]
  23. Dieffenbach CW (2012). Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: Aspects of an emerging scientific agenda. Current Opinion in HIV and AIDS, 7(2), 106–110. [DOI] [PubMed] [Google Scholar]
  24. Gardner EM, McLees MP, Steiner JF, Del Rio C, & Burman WJ (2011). The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases, 52(6), 793–800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gill H, Babatunde O, & Weissman S (2017). Social determinants of health and disparities in linkage to care among newly diagnosed HIV cases–South Carolina, 2009–2011. Open Forum Infectious Diseases, 4(Suppl. 1), S419–S420. [Google Scholar]
  26. Gill CJ, Griffth JL, Jacobson D, Skinner S, Gorbach SL, & Wilson IB (2002). Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life. JAIDS Journal of Acquired Immune Deficiency Syndromes, 30(5), 485–492. [DOI] [PubMed] [Google Scholar]
  27. Girardi E, Sabin CA, & Monforte AD (2007). Late diagnosis of HIV infection: Epidemiological features, consequences and strategies to encourage earlier testing. JAIDS Journal of Acquired Immune Deficiency Syndromes, 46 (Suppl. 1), S3–S8. doi: 10.1097/01.qai.0000286597.57066.2b [DOI] [PubMed] [Google Scholar]
  28. Grabowski MK, Reynolds SJ, Kagaayi J, Gray RH, Clarke W, Chang LW, … Billioux V (2018). The validity of self-reported antiretroviral use in persons living with HIV: A population-based study. AIDS, 32(3), 363–369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Greenland S, Mansournia MA, & Altman DG (2016). Sparse data bias: A problem hiding in plain sight. BMJ, 352, i1981. [DOI] [PubMed] [Google Scholar]
  30. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, … HER Study Group. (2002). A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS, 16(16), 2175–2182. [DOI] [PubMed] [Google Scholar]
  31. Hussen SA, Easley KA, Smith JC, Shenvi N, Harper GW, Camacho-Gonzalez AF, … Del Rio C (2018). Social capital, depressive symptoms, and HIV viral suppression among young Black, gay, bisexual and other men who have sex with men living with HIV. AIDS and Behavior, 22(9), 3024–3032. doi: 10.1007/s10461-018-2105-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kalichman SC, Benotsch E, Suarez T, Catz S, Miller J, & Rompa D (2000). Health literacy and health-related knowledge among persons living with HIV/AIDS. American Journal of Preventive Medicine, 18(4), 325–331. [DOI] [PubMed] [Google Scholar]
  33. Kalichman SC, Ramachandran B, & Catz S (1999). Adherence to combination antiretroviral therapies in HIV patients of low health literacy. Journal of General Internal Medicine, 14(5), 267–273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kalichman SC, & Rompa D (2000). Functional health literacy is associated with health status and health-related knowledge in people living with HIV-AIDS. JAIDS Journal of Acquired Immune Deficiency Syndromes, 25(4), 337–344. [DOI] [PubMed] [Google Scholar]
  35. Land E (2018, March 8). Fact sheet: Undetectable viral load. Retrieved from https://www.sfaf.org/collections/beta/factsheet-undetectable-viral-load/
  36. Le Moing V, Chene G, Carrieri MP, Alioum A, BrunVezinet F, Piroth L, … Aproco Study Group. (2002). Predictors of virological rebound in HIV1-infected patients initiating a protease inhibitor-containing regimen. AIDS, 16(1), 21–29. [DOI] [PubMed] [Google Scholar]
  37. Mugavero MJ, Amico KR, Horn T, & Thompson MA (2013). The state of engagement in HIV care in the United States: From cascade to continuum to control. Clinical Infectious Diseases, 57(8), 1164–1171. [DOI] [PubMed] [Google Scholar]
  38. Nance RM, Delaney JAC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, … Crane HM (2018). HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: A cohort study. Annals of Internal Medicine, 169(6), 376–384. doi: 10.7326/M17-2242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. PAC. (2016). Undetectable=untransmittable. Retrieved from https://www.preventionaccess.org/undetectable
  40. Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, … Hogg RS (2011). Women and vulnerability to HAART non-adherence: A literature review of treatment adherence by gender from 2000 to 2011. Current HIV/AIDS Reports, 8(4), 277–287. doi: 10.1007/s11904-011-0098-0 [DOI] [PubMed] [Google Scholar]
  41. Reif S, Safley D, McAllaster C, Wilson E, & Whetten K (2017). State of HIV in the US Deep South. Journal of Community Health, 42(5), 844–853. [DOI] [PubMed] [Google Scholar]
  42. Saracino A, Lorenzini P, Lo Caputo S, Girardi E, Castelli F, Bonfanti P, … ICONA Foundation Study Group. (2016). Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort. Clinical Microbiology and Infection, 22(3), 288.e1–288.e8. doi: 10.1016/j.cmi.2015.10.026 [DOI] [PubMed] [Google Scholar]
  43. SCDHEC. (2017). An epidemiologic profile of HIV and AIDS in South Carolina. Retrieved from https://scdhec.gov/sites/default/files/docs/Health/docs/stdhiv/pp_CH1-EpiProfile.pdf
  44. Sewell J, Daskalopoulou M, Nakagawa F, Lampe F, Edwards S, Perry N, … Rodger AJ (2017). Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment. HIV Medicine, 18(7), 463–473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, & Pawaskar M (2010). Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics, 28(12), 1097–1107. doi: 10.2165/11537400-000000000-00000 [DOI] [PubMed] [Google Scholar]
  46. Sithole Z, Mbizvo E, Chonzi P, Mungati M, Juru TP, Shambira G, … Tshimanga M (2018). Virological failure among adolescents on ART, Harare City, 2017- a case-control study. BMC Infectious Diseases, 18(1), 469. doi: 10.1186/s12879-018-3372-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, … Mermin JH (2015). Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Internal Medicine, 175(4), 588–596. [DOI] [PubMed] [Google Scholar]
  48. StataCorp. (2015). Stata statistical software: Release 14.2. College Station, TX: https://www.stata.com/support/faqs/resources/citing-software-documentation-faqs/ [Google Scholar]
  49. Sun G-W, Shook TL, & Kay GL (1996). Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. Journal of Clinical Epidemiology, 49(8), 907–916. [DOI] [PubMed] [Google Scholar]
  50. Ti L, Milloy MJ, Shannon K, Simo A, Hogg RS, Guillemi S, … Wood E (2014). Suboptimal plasma HIV1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: An observational cohort study. Sexually Transmitted Infections, 90(5), 418–422. doi: 10.1136/sextrans-2013-051408 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. UNAIDS. (2018). Undetectable = untransmittable. Retrieved from https://www.unaids.org/en/resources/presscentre/featurestories/2018/july/undetectable-untransmittable
  52. Weiser SD, Bangsberg DR, Kegeles S, Ragland K, Kushel MB, & Frongillo EA (2009). Food insecurity among homeless and marginally housed individuals living with HIV/AIDS in San Francisco. AIDS and Behavior, 13(5), 841–848. doi: 10.1007/s10461-009-9597-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. The White House. (2016). National HIV/AIDS strategy for the United States: Updated to 2020. Washington, DC: Retrieved from https://files.hiv.gov/s3fs-public/nhas-indicators-supplement-de016.pdf [Google Scholar]
  54. Xia Q, Robbins RS, Lazar R, Torian LV, & Braunstein SL (2017). Racial and socioeconomic disparities in viral suppression among persons living with HIV in New York City. Annals of Epidemiology, 27(5), 335–341. doi: 10.1016/j.annepidem.2017.04.005 [DOI] [PubMed] [Google Scholar]

RESOURCES